Scienture Holdings, Inc. has entered into a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million.
Offering Details
3,225,000 shares of common stock at $1.20 per share.
Gross Proceeds
Expected to be approximately $3.9 million before deductions.
Closing Date
Expected to be August 15, 2025, subject to customary conditions.
- The offering is being made through Maxim Group LLC as the sole placement agent.
- The offering is pursuant to an effective shelf registration statement on Form S-3 filed with the SEC.
- Investors can access additional information through the SEC's website and prospectus supplement.
Scienture Holdings, Inc.'s securities purchase agreement represents a significant milestone in enhancing value for patients and caregivers through innovative pharmaceutical products.